September 10, 2017 8:59 am | Leave your thoughts
Clinical trials are constantly evolving, with more data being collected in reflection to an increasingly complex environment. New technology, regulations, legislation and reforms in the pharmaceutical sector result in an environment that is always evolving. What does the future hold for clinical trials and what changes can we expect? Siteless Clinical Trials Siteless clinical trials
August 7, 2017 2:25 pm | Leave your thoughts
China’s central government have introduced reforms in response to an increasingly challenging regulatory environment. These are likely to benefit medicine access as well as drug development, affecting those looking into China’s pharmaceutical market, which is the second largest in the world. In a long-awaited response to feedback from the local and international pharmaceutical industry, the
July 16, 2017 2:02 pm | Leave your thoughts
The demands of clinical trial supply are constantly evolving, with the industry moving towards ever-more-elaborate studies and adaptive clinical trial designs. The progressive developments created by such factors can cause challenges for the clinical supply chain; so, when it comes to managing your global clinical supplies, it’s vital to choose a partner who sticks to
July 4, 2017 3:28 pm | Leave your thoughts
Now that the UK has triggered Article 50, an important topic on many minds is how Britain’s exit from the European Union will affect clinical trials. Could Brexit benefit clinical trials? It is believed by some that the EU clinical trials directive has slowed the pace of research Britain has performed over the years and
June 20, 2017 3:22 pm | Leave your thoughts
Small changes can have a big impact on the overall success of a clinical trial, having a significant effect on the clinical supply chain and even putting it at risk. Here are 4 factors that can have a knock-on effect on your clinical supply chain. Delays in Manufacture, Procurement and/or Packaging It can be frustrating
May 18, 2017 3:26 pm | Leave your thoughts
At the New York Academy of Sciences’ symposium on Equivalence of Complex Drug Products: Scientific and Regulatory Challenges, regulatory officials described how agencies approach evaluating complex generics for marketing approval. In 2015, almost 90% of prescriptions in the United States were for generics, according to the Generic Pharmaceutical Association. However, there are certain complex drug
April 18, 2017 1:00 pm | Leave your thoughts
False medicines can present a huge health risk to the public. As well as potentially damaging the reputations of pharmaceutical companies, they can disrupt comparator sourcing and clinical trials services. The number of illegitimate and counterfeit medicines across the globe is becoming increasingly concerning, as they have even been appearing in the legitimate medical supply
April 3, 2017 1:10 am | Leave your thoughts
Clinical trial supply is, to state the obvious, an expensive and multifaceted activity which continues to get more complex. Over the past 5 years, factors have extended this trend; for example: Changes in and development of legislation – New EU Clinical Trial regulations (No 536/2014), the Falsified Medicines Directive, US FDA Drug Supply Chain Security
February 7, 2017 10:06 am | Leave your thoughts
It has been noted that older, off-patent drugs are becoming increasingly expensive. But what are the underlying causes of the problem and how can policymakers address it? In August 2015, a pharmaceutical company increased the price of Daraprim (pyrimethamine), its newly acquired 62-year-old infectious disease drug. Due to the limited patient population and lack of
January 23, 2017 11:28 am | Leave your thoughts
We are very pleased to announce the appointment of Mark Johnson as the new Director of Clinical Trial Services at Client Pharma CTS. Mark’s considerable knowledge of the global pharmaceutical supply chain and experience within the industry furthers Client Pharma CTS’s ability to support manufacturers, sponsors, biotechs, CROs and patients alike. He will be playing
